Background
Clear cell renal cell carcinoma (ccRCC) exhibits significant heterogeneity due to morphological changes and tumor microenvironment dynamics, influencing systemic therapy responses. While the role of high-mobility group AT-hook 2 (HMGA2) in …
Background
Immunotherapy has emerged as a promising avenue for malignant tumors treatment, but methods to validate its in vivo antitumor activity remain limited. Granzyme B, a key mediator of immune-mediated cell death, is a potential biomarker for as…
Background
Immunotherapy has emerged as a promising avenue for malignant tumors treatment, but methods to validate its in vivo antitumor activity remain limited. Granzyme B, a key mediator of immune-mediated cell death, is a potential biomarker for as…
Background
Immunotherapy resistance in microsatellite-stable colorectal cancer (CRC) remains a major therapeutic challenge. Recent strategies to overcome the immunosuppressive tumor microenvironment have focused on reactivating innate immune pathways,…
Background
While CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapies have shown efficacy in B-cell hematological malignancies, treatment of antigen-negative or relapsed tumors remains challenging. The recombinant malaria protein VAR2CSA …
Background
Neoadjuvant chemoimmunotherapy (NACI) shows promise for locally advanced cervical cancer (LACC), but drug-tolerant persister (DTP) cells and immunosuppressive microenvironmental adaptations limit clinical efficacy. The underlying determinan…
Background
PD-1/PD-L1 blockade therapy is often used in combination with radiotherapy (RT) to enhance therapeutic efficacy in clinic. However, the effectiveness of the combination therapy is still unsatisfactory due to the blindness in the administrat…
Background
Chimeric antigen receptor macrophage (CAR-M) therapy has promising therapeutic potential in solid tumors, yet challenges remain in target compatibility and systemic toxicity.
Methods
In this study, we screened the CD47-scFv sequence of CAR…
Background
Chimeric antigen receptor (CAR) T cells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome (CRS) limit their broader application. Current preclinica…
Background
Despite remarkable advances in cancer immunotherapy, including immune checkpoint inhibitors and adoptive cell therapies, many patients fail to achieve durable responses due to factors such as immunosuppressive tumor microenvironments, poor …
